# CTSN Embolic Protection Trial

Study · id `cardio:ct-nct06027788` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06027788](<https://clinicaltrials.gov/study/NCT06027788>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06027788

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 842 participants.

## Technical summary

Registry record NCT06027788. Randomized; single masking; primary purpose prevention. Start 2023-09-18 (actual); primary completion 2027-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 842 participants (planned count; ClinicalTrials.gov record NCT06027788, source copy `cardio:ctgov-nct06027788-2026-10-02`, retrieved 2026-10-26)
- Started: 2023-09-18 (actual) (ClinicalTrials.gov record NCT06027788, source copy `cardio:ctgov-nct06027788-2026-10-02`, retrieved 2026-10-26)
- Primary completion: 2027-04-01 (anticipated) (ClinicalTrials.gov record NCT06027788, source copy `cardio:ctgov-nct06027788-2026-10-02`, retrieved 2026-10-26)
- Completion: 2027-04-01 (anticipated) (ClinicalTrials.gov record NCT06027788, source copy `cardio:ctgov-nct06027788-2026-10-02`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT06027788, source copy `cardio:ctgov-nct06027788-2026-10-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06027788-2026-10-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: CTSN Embolic Protection Trial
- Acronym: EMPRO
- Condition: Delirium
- Condition: Ischemic Stroke
- Condition: Acute Kidney Injury
- Condition: Heart Valve Disease
- Condition: Coronary Artery Disease
- Intervention (Device): CardioGard Embolic Protection Cannula
- Intervention (Device): Standard Aortic Cannula
- Lead sponsor: Icahn School of Medicine at Mount Sinai
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Icahn School of Medicine at Mount Sinai (`cardio:org-icahn-school-of-medicine-at-mount-sinai`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: 5c3d26b4ef3d401065cfe035f77cc34cbaefb3fc5c5e499cc7fa1be9ee6ccb06
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
